Ming Yan's most recent trade in Cytek BioSciences Inc was a trade of 135,892 Common Stock done . Disclosure was reported to the exchange on June 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Jun 2026 | 135,892 | 4,796,688 | - | 0 | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 9,480 | 4,934,944 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 9,480 | 218,055 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 4,908 | 24,552 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 4,908 | 4,920,841 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 4,108 | 69,850 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 4,108 | 4,926,489 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 3,683 | 40,520 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 3,683 | 4,923,300 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 2,364 | 4,932,580 | - | 3.5 | 8,392 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 1,224 | 4,919,617 | - | 3.5 | 4,345 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 1,025 | 4,925,464 | - | 3.6 | 3,639 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 919 | 4,922,381 | - | 3.5 | 3,262 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Mar 2026 | 1,176,000 | 4,915,933 | - | 0 | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 227,535 | 227,535 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 120,688 | 120,688 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 9,817 | 29,460 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 9,817 | 6,084,081 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 8,217 | 73,958 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 8,217 | 6,094,330 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 7,366 | 44,203 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 7,366 | 6,088,400 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 3,047 | 6,081,034 | - | 4.2 | 12,889 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 2,397 | 6,091,933 | - | 4.2 | 10,139 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 2,287 | 6,086,113 | - | 4.2 | 9,674 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 1,332 | 0 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 1,332 | 6,074,659 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.20 per share. | 18 Feb 2026 | 395 | 6,074,264 | - | 4.2 | 1,659 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 7,363 | 39,277 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 7,363 | 6,066,280 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 6,162 | 82,175 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 6,162 | 6,074,828 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 5,525 | 51,569 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 5,525 | 6,070,012 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 1,981 | 1,332 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 1,981 | 6,059,400 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 1,793 | 6,064,487 | - | 5.5 | 9,915 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 1,501 | 6,073,327 | - | 5.5 | 8,301 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 1,346 | 6,068,666 | - | 5.5 | 7,443 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 483 | 6,058,917 | - | 5.5 | 2,671 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 7,363 | 46,640 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 7,363 | 6,050,882 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 6,162 | 6,058,887 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 6,162 | 88,337 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 5,525 | 57,094 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 5,525 | 6,054,223 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 2,184 | 6,048,698 | - | 4.1 | 8,867 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 1,981 | 3,313 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 1,981 | 6,044,107 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 1,498 | 6,052,725 | - | 4.1 | 6,082 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 1,468 | 6,057,419 | - | 4.1 | 5,960 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 588 | 6,043,519 | - | 4.1 | 2,387 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 4,908 | 54,003 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 4,908 | 6,038,103 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 4,108 | 94,499 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 4,108 | 6,043,345 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 3,683 | 62,619 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 3,683 | 6,040,330 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 1,981 | 5,294 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 1,981 | 6,033,783 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 1,456 | 6,036,647 | - | 2.7 | 3,917 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 1,219 | 6,042,126 | - | 2.7 | 3,279 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 1,093 | 6,039,237 | - | 2.7 | 2,940 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 588 | 6,033,195 | - | 2.7 | 1,582 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 9,817 | 6,029,532 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 9,817 | 58,911 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 7,366 | 66,302 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 7,366 | 6,033,987 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 2,911 | 6,026,621 | - | 4.4 | 12,692 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 2,185 | 6,031,802 | - | 4.4 | 9,527 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 156,250 | 156,250 | - | - | Employee Stock Option (right to buy) | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 98,607 | 98,607 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 1,981 | 7,275 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 1,981 | 6,020,303 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.31 per share. | 18 Feb 2025 | 588 | 6,019,715 | - | 5.3 | 3,122 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 7,363 | 68,728 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 7,363 | 6,015,936 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 5,525 | 73,668 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 5,525 | 6,019,668 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 1,981 | 9,256 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 1,981 | 6,009,056 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 1,793 | 6,014,143 | - | 6.0 | 10,812 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 1,346 | 6,018,322 | - | 6.0 | 8,116 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 18 Nov 2024 | 483 | 6,008,573 | - | 6.0 | 2,912 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 7,363 | 76,091 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 7,363 | 6,004,693 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 5,525 | 79,193 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 5,525 | 6,008,421 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 1,981 | 5,997,918 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 1,981 | 11,237 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 1,797 | 6,002,896 | - | 5.5 | 9,937 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 1,346 | 6,007,075 | - | 5.5 | 7,443 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 19 Aug 2024 | 588 | 5,997,330 | - | 5.5 | 3,252 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 4,980 | 83,454 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 4,908 | 5,994,803 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 3,683 | 84,718 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 3,683 | 5,997,030 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 1,981 | 13,218 | - | - | Restricted Stock Units | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 1,981 | 5,990,483 | - | - | Common Stock | |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.96 per share. | 20 May 2024 | 1,456 | 5,993,347 | - | 6.0 | 8,678 | Common Stock |
| Cytek BioSciences Inc | Ming Yan | Director, CHIEF TECHNOLOGY OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.96 per share. | 20 May 2024 | 1,093 | 5,995,937 | - | 6.0 | 6,514 | Common Stock |